Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

NCT00956761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Influenza

Interventions

BIOLOGICAL: Seasonal Influenza Vaccine (MF59C.1)

Sponsor

Novartis

Collaborators

[object Object]